As several companies advance in developing biosimilars for Keytruda, Merck & Co. has introduced Keytruda Qlex – a subcutaneous formulation of their leading cancer therapy. Industry analysts suggest this innovative launch is strategically positioned to help cushion the impact of Keytruda’s anticipated patent expiration in 2028. The impending expiration of Keytruda’s patents is projected to significantly affect Merck’s financial performance. In 2024, Keytruda achieved noteworthy sales of $29.5 billion, with forecasts indicating growth to nearly $32.7 billion by 2026. Despite forecasts predicting Keytruda sales will dwindle to just over $7 billion by 2032, the recent FDA approval of Keytruda Qlex on September 19, 2025, is expected to gain traction quickly. While the combined revenues of Keytruda and Keytruda Qlex may not match the original peak of Keytruda alone, current projections for 2028 and 2029 indicate a more stable outlook for Merck & Co., avoiding the steep revenue decline previously anticipated.
https://www.merck.com/news/fda-approves-mercks-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-injection-for-subcutaneous-use-in-adults-across-most-solid-tumor-indications-for-keytruda-pem/
